Evidence map›Paper›PMID 27548466›Full record

ReviewBone marrow transplantation2017

Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT.

Z DeFilipp, R F Duarte, J A Snowden, N S Majhail, D M Greenfield, J L Miranda, M Arat, K S Baker, L J Burns, C N Duncan and 27 more

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Bone marrow transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Association Between Body Composition and Development of Glucose Intolerance after Allogeneic Hematopoietic Cell Transplantation.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors at 20 institutions in 8 countries.

Z DeFilippDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
R F DuarteHospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
J A SnowdenDepartment of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust and Department of Oncology & Metabolism, University of Sheffield, Sheffield, UK.
N S MajhailDepartment of Hematology and Oncology, Cleveland Clinic, Cleveland, OH, USA.
D M GreenfieldSpecialized Cancer Services, Sheffield Teaching Hospital NHS Foundation Trust, Shefflied, UK.
J L MirandaDepartment of Medicine, Reina Sofia University Hospital, Maimonides Institute for Biomedical Research at Cordoba (IMIBIC), University of Cordoba, CIBER Fisiopatología Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.
M AratFlorence Nightingale Sisli Hospital, Hematopoietic Stem Cell Transplantation Unit, Istanbul, Turkey.
K S BakerClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
L J BurnsNational Marrow Donor Program, University of Minnesota, Minneapolis, MN, USA.
C N DuncanPediatric Stem Cell Transplant, Dana-Farber Cancer Institute, Boston, MA, USA.
M GilleeceLeeds Teaching Hospitals NHS Trust, Leeds, UK.
G A HaleAll Children's Hospital, John Hopkins Medicine, St. Petersburg, FL, USA.
M HamadaniDepartment of Medicine, Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI, USA.
B K HamiltonDepartment of Hematology and Oncology, Cleveland Clinic, Cleveland, OH, USA.
W J HoganDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
J W HsuDivision of Hematology & Oncology, Department of Medicine, University of Florida, Gainesville, FL, USA.
Y InamotoDivision of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
R T KambleDivision of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA.
M T Lupo-StanghelliniHematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milano, Italy.
A K MaloneDivision of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
P McCarthyDepartment of Medicine, Roswell Park Cancer Institute, BMT Program, Buffalo, NY, USA.
M MohtyUniversity Pierre & Marie Curie, Paris, France.
M NorkinDivision of Hematology & Oncology, Department of Medicine, University of Florida, Gainesville, FL, USA.
P PaplhamDepartment of Medicine, Roswell Park Cancer Institute, BMT Program, Buffalo, NY, USA.
M RamanathanDepartment Hematology, Oncology and Bone Marrow Transplant, UMass Memorial Medical Center, Worcester, MA, USA.
J M RichartDivision of Hematology and Medical Oncology, Department of Internal Medicine, Saint Louis University, St. Louis, MO, USA.
N SaloojaHammersmith Hospital, London, UK.
H C SchoutenMaastricht University Medical Center, Maastricht, The Netherlands.
H SchoemansDepartment of Hematology, University Hospital Leuven and KU Leuven, Leuven, Belgium.
A SeberHospital Samaritano, Sao Paulo, Brazil.
A SteinbergDivision of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
B M WirkDepartment of Internal Medicine, Stony Brook University Medical Center, Stony Brook, NY, USA.
W A WoodDivision of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.
M BattiwallaHematology Branch, National Institutes of Health, Bethesda, MD, USA.
M E D FlowersClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
B N SavaniDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
B E ShawDepartment of Medicine, Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI, USA.
Cleveland Clinic · USFred Hutch Cancer Center · USIcahn School of Medicine at Mount Sinai · USMedical College of Wisconsin · USRoswell Park Comprehensive Cancer Center · USSheffield Teaching Hospitals NHS Foundation Trust · GBUniversity of Florida · USBaylor College of Medicine · USBrazilian Medical Association · BRDana-Farber Cancer Institute · USEmory University · USHammersmith Hospital · GBHospital Universitario Puerta de Hierro Majadahonda · ESInserm · FRInstituto de Salud Carlos III · ESIstanbul Florence Nightingale Hospital · TRJohns Hopkins University · USKU Leuven · BELeeds Teaching Hospitals NHS Trust · GBMaastricht University · NL

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
NCI NIH HHS U24 CA076518
6 · The paper itself

Abstract

Metabolic syndrome (MetS) is a constellation of cardiovascular risk factors that increases the risk of cardiovascular disease, diabetes mellitus and all cause mortality. Long-term survivors of hematopoietic cell transplantation (HCT) have a substantial risk of developing MetS and cardiovascular disease, with the estimated prevalence of MetS being 31-49% among HCT recipients. Although MetS has not yet been proven to impact cardiovascular risk after HCT, an understanding of the incidence and risk factors for MetS in HCT recipients can provide the foundation to evaluate screening guidelines and develop interventions that may mitigate cardiovascular-related mortality. A working group was established through the Center for International Blood and Marrow Transplant Research and the European Group for Blood and Marrow Transplantation with the goal of reviewing literature and recommend practices appropriate to HCT recipients. Here we deliver consensus recommendations to help clinicians provide screening and preventive care for MetS and cardiovascular disease among HCT recipients. All HCT survivors should be advised of the risks of MetS and encouraged to undergo recommended screening based on their predisposition and ongoing risk factors.

Indexed as

Cardiovascular DiseasesMetabolic SyndromeAllograftsHematopoietic Stem Cell TransplantationHumansPractice Guidelines as Topic

Identifiers

PMID27548466
PMCPMC5288134
OpenAlexW2409486903

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.